Turning Point Therapeutics Insights
Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.
A sample of Turning Point Therapeutics Insights data
Headline | Published | Journalists |
---|---|---|
Deserunt mollit sunt Lorem laborum do id aliqua dolore | 13 Jun 2019 | Lorem |
Turning Point’s repotrectinib likely limited to later-line uptake in a crowded ROS1+ NSCLC space despite significant Phase I data, experts say | 13 Jun 2019 | Manasi Vaidya |
Pfizer’s Lorbrena in ROS1+ NSCLC Xalkori-treated patients to be presented in September at World Conference on Lung Cancer, source says | 05 Jun 2019 | Manasi Vaidya |
TP Therapeutics aims to submit Phase I data for anticancer agent TPX-0005 to ASCO 2018 - CEO | 13 Dec 2017 | Manasi Vaidya |
Feature
Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.
Benefit
Drug Insights:
- Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
- Material intelligence on competitors, including breaking news
- Insight on companies’ business development needs and strategies
Outsourcing Insights:
Insight on companies’ CRO and business development needs, strategies and relationships
Value
Remove risk and uncertainty
Gain a competitive edge
Secure actionable leads
Premium databases is part of our industry range of products
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward